A stark transatlantic regulatory divide isolates patients in one hemisphere from life-changing orphan therapies.
The growing regulatory and philosophical division between the FDA and the EMA over historical data validity and trial endpoints splits the market, stranding patients with rare diseases without approved treatments in one region.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
European regulators refused approval for the rare-disease therapy, preventing patients in Europe from accessing a drug already cleared in the US.
The divergent approvals of Yartemlea leave European patients without access to a critical orphan therapy that was approved in the US.
European approvals based on a landmark neuroinflammation trial have not been matched in the U.S., stalling patient access to the first disease-progression multiple sclerosis therapy.
European regulators rejected the marketing application for this critical rare-disease drug, creating a stark market divide from the approved US pathway.
Divergent regulatory assessments between Europe and the US leave European patients without access to a newly approved orphan therapy.